PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) today announced results of new data from the University of Illinois College of Medicine analyzing the impact of EXPAREL® (bupivacaine liposome injectable suspension) used to manage postsurgical pain following total knee replacement surgery. The data found EXPAREL use associated with improved clinical outcomes and a favorable cost savings per patient compared to the standard of care. The results were presented today at the 27th annual meeting and expo of the Academy of Managed Care Pharmacy in San Diego from April 7-10.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
